International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
31
07
2018
accepted:
19
03
2019
revised:
15
03
2019
pubmed:
12
4
2019
medline:
11
3
2020
entrez:
12
4
2019
Statut:
ppublish
Résumé
Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer. In the current study, we report on uptake of cancer screening and risk-reduction options in a cohort of BRCA mutation carriers from ten countries over two time periods (1995 to 2008 and 2009 to 2017). Eligible subjects were identified from an international database of female BRCA mutation carriers and included women from 59 centres from ten countries. Subjects completed a questionnaire at the time of genetic testing, which included past use of cancer prevention options and screening tests. Biennial follow-up questionnaires were administered. Six-thousand two-hundred and twenty-three women were followed for a mean of 7.5 years. The mean age at last follow-up was 52.1 years (27-96 years) and 42.3% of the women had a prior diagnosis of breast cancer. In all, 27.8% had a prophylactic bilateral mastectomy and 64.7% had a BSO. Screening with breast MRI increased from 70% before 2009 to 81% at or after 2009. There were significant differences in uptake of all options by country. For women who received genetic testing more recently, uptake of prophylactic mastectomy and breast MRI is significantly higher than those who received genetic testing more than 10 years ago. However, uptake of both BSO and breast MRI is not optimal, and interventions to increase uptake are needed.
Sections du résumé
BACKGROUND
Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer. In the current study, we report on uptake of cancer screening and risk-reduction options in a cohort of BRCA mutation carriers from ten countries over two time periods (1995 to 2008 and 2009 to 2017).
METHODS
Eligible subjects were identified from an international database of female BRCA mutation carriers and included women from 59 centres from ten countries. Subjects completed a questionnaire at the time of genetic testing, which included past use of cancer prevention options and screening tests. Biennial follow-up questionnaires were administered.
RESULTS
Six-thousand two-hundred and twenty-three women were followed for a mean of 7.5 years. The mean age at last follow-up was 52.1 years (27-96 years) and 42.3% of the women had a prior diagnosis of breast cancer. In all, 27.8% had a prophylactic bilateral mastectomy and 64.7% had a BSO. Screening with breast MRI increased from 70% before 2009 to 81% at or after 2009. There were significant differences in uptake of all options by country.
CONCLUSION
For women who received genetic testing more recently, uptake of prophylactic mastectomy and breast MRI is significantly higher than those who received genetic testing more than 10 years ago. However, uptake of both BSO and breast MRI is not optimal, and interventions to increase uptake are needed.
Identifiants
pubmed: 30971774
doi: 10.1038/s41416-019-0446-1
pii: 10.1038/s41416-019-0446-1
pmc: PMC6738089
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-21Commentaires et corrections
Type : CommentIn
Références
Breast. 2007 Aug;16(4):367-74
pubmed: 17317184
Eur J Cancer. 2013 Sep;49(13):2798-805
pubmed: 23692813
N Engl J Med. 2004 Jul 29;351(5):427-37
pubmed: 15282350
J Clin Oncol. 2005 Nov 20;23(33):8469-76
pubmed: 16293877
Breast Cancer Res Treat. 2016 Jun;157(2):319-327
pubmed: 27117159
Breast Cancer Res Treat. 2014 Dec;148(3):687-8
pubmed: 25398653
Breast J. 2016 Jan-Feb;22(1):10-7
pubmed: 26782950
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2318-24
pubmed: 19661091
Radiology. 2007 Aug;244(2):381-8
pubmed: 17641362
N Engl J Med. 1999 Jan 14;340(2):77-84
pubmed: 9887158
J Clin Oncol. 2004 Mar 15;22(6):1055-62
pubmed: 14981104
Int J Cancer. 2008 May 1;122(9):2017-22
pubmed: 18196574
J Breast Cancer. 2017 Jun;20(2):203-207
pubmed: 28690658
JAMA. 2006 Jul 12;296(2):185-92
pubmed: 16835424
N Engl J Med. 2002 May 23;346(21):1616-22
pubmed: 12023993
J Clin Oncol. 2001 Aug 1;19(15):3524-31
pubmed: 11481359
J Clin Oncol. 2014 May 20;32(15):1547-53
pubmed: 24567435
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Med J Aust. 2013 Nov 18;199(10):680-3
pubmed: 24237098
Lancet. 2000 Jun 10;355(9220):2015-20
pubmed: 10885351
Cancer. 2005 May 1;103(9):1898-905
pubmed: 15800894
Breast Cancer Res. 2014 Sep 19;16(5):442
pubmed: 25510853
JAMA. 2010 Sep 1;304(9):967-75
pubmed: 20810374
Hered Cancer Clin Pract. 2016 Apr 14;14:8
pubmed: 27087880
Cancers (Basel). 2018 Nov 30;10(12):
pubmed: 30513626
JAMA Surg. 2018 Feb 1;153(2):123-129
pubmed: 28903167
Breast Cancer Res. 2015 Nov 25;17:143
pubmed: 26603733
N Engl J Med. 2001 Jul 19;345(3):159-64
pubmed: 11463009
Fam Cancer. 2012 Sep;11(3):473-82
pubmed: 22711610
JAMA. 2004 Sep 15;292(11):1317-25
pubmed: 15367553
Radiology. 2007 Mar;242(3):698-715
pubmed: 17244718
J Natl Cancer Inst. 2001 Nov 7;93(21):1633-7
pubmed: 11698567